arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

60 DEGREES PHARMACEUTICALS, INC.

SXTP

$1.14 ▲ +0.10 (+9.62%) at close

5 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Moderately Bearish

auto_awesome

Analytical Summary

60 DEGREES PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —

Dividend Yield —

Revenue Growth 65.5% ↘

Op. Margin —

ROIC -214.7% ↗

FCF / Share $-10.43 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity 0.04

info Valuation on last close. End-of-day price, Sep 23, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.01M

↑ +65.5% —

Net Income Profit after all expenses

$-7.37M

↑ +7.3% —

FCF / Share Free cash flow per share

$-10.43

↑ +17.6% —

Long-Term Debt Long-term obligations

$150.00K

— 0.0% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health →

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Revenue Growth YoY (%)	65.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+719%)	139.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1645%)	13.6% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+70%)	—	—
EPS Growth YoY (%)	36.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	68.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-2167.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	7.3% Fair ↑ Fair Improving Year-over-year change in net income	-111.0% Weak Weak Year-over-year change in net income	39.1% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	17.6% Good Good Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	65.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF Margin (%) (%)	—	—	—	-452.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.22x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Return on Invested Capital (%)	-214.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-232.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-105.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	7.4% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-144.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-168.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-66.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-134.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-212.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1518%)	-196.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1413%)	-77.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-615%)	26.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+75%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Debt to Equity (x)	0.04x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-93%)	0.04x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-94%)	—	—	—
Interest Coverage (x)	-884.47x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-77.44x Weak Weak Operating income divided by interest expense Optimal: > 5x	-0.44x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-1.36M	$-1.51M	$-2.14M	—	—
Debt / EBITDA (x)	-0.02x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.02x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Revenue per Share (USD)	$1.50	$1.34	—	$0.09	—
Basic EPS, GAAP (USD)	$-11.73	$-18.55	$-59.18	$-2.61	—
Free Cash Flow per Share (USD)	$-10.43	$-12.65	—	$-0.43	—
Book Value per Share (USD)	$2.98	$7.12	—	$-9.96	—
Tangible Book Value per Share (USD)	$2.78	$6.84	—	$-10.03	—
Basic Weighted Avg Shares (shares)	670,211	454,582	66,314	2.37M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Working Capital (USD)	$3.05M	$3.73M	$4.41M	$-22.82M	—
LT Debt (USD)	$150.00K	$150.00K	—	—	—
Total Equity (USD)	$3.46M	$4.04M	$4.87M	$-23.58M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$1.01M	$607.57K	$253.57K	$223.21K	—
Depreciation Expense (USD)	$43.32K	$11.73K	$21.16K	$27.65K	—
Net Income, GAAP (USD)	$-7.37M	$-7.95M	$-3.77M	$-6.18M	—
Operating Cash Flow (USD)	$-6.85M	$-5.65M	$-4.54M	$-1.01M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters

60 DEGREES PHARMACEUTICALS, INC.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SXTP with peers